Resultado de búsqueda
Hace 11 horas · La pastilla de Bristol, ... (Penn Medicine) Las acciones de Bristol subieron un 0,9% en la apertura del mercado de Nueva York, después de perder casi un 20% este año hasta el cierre del viernes.
Hace 4 días · Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration for Breyanzi (lisocabtagene maraleucel; liso-cel) to treat adults with relapsed or refractory mantle cell lymphoma (MCL). The CD19-directed chimeric antigen receptor (CAR) T cell therapy is indicated for MCL patients who have received a minimum of two ...
Hace 5 días · NEW YORK – The US Food and Drug Administration on Thursday approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory mantle cell lymphoma. The agency approved the CD19-directed CAR T-cell therapy for mantle cell lymphoma patients who previously received at least two prior lines of therapy ...
Hace 5 días · Empresa reclamada: Bristol Medicine Hola !! ya van varias veces que se atrasan en autorizar estudios tengo mi señora embarazada de 8 meses y no puede estar esperando mucho tiempo la autorizacion y encima cuando la mandan mandan una autorizacion vieja que nada que ver con lo que pedimos
Hace 1 día · It’s no secret that the field of nuclear medicine has occasionally been hamstrung by supply constraints. Now, RazyeBio, the company at the center of Bristol Myers Squibb’s recent $4.1 billion ...
Hace 11 horas · ‘’ The neuropsychiatric space has been gaining traction as “success builds on success,” Butts said, pointing to the recent $14 billion acquisition of Karuna Therapeutics and its schizophrenia asset, KarXT, by Bristol Myers Squibb. BMS is already seeing a return on its investment as Phase III in April showed significant and sustained symptom improvement in patients taking KarXT. If ...
Hace 4 días · A neurodevelopmental disorder, caused by mutations in a single gene, affecting tens of thousands of people worldwide, has been identified by researchers. The work, published today [31 May] in Nature Medicine, was conducted by researchers at the Icahn School of Medicine at Mount Sinai, New York in collaboration with colleagues at the University of Bristol, KU Leuven, Belgium; and the NIHR ...
